Guido Bocci

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi request reprint The effect of osteogenic growth peptide (OGP) on proliferation and adhesion of HEMC-1 human endothelial cells
    Guido Bocci
    Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy
    Pharmacol Res 45:21-5. 2002
  2. pmc Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo
    Bastianina Canu
    Division of Pharmacology, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Neoplasia 13:217-29. 2011
  3. doi request reprint CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo
    Alessandro Antonelli
    Department of Internal Medicine, University of Pisa, School of Medicine, Via Roma, 67, 56100, Pisa, Italy
    J Clin Endocrinol Metab 97:E528-36. 2012
  4. doi request reprint Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer
    Anna Fioravanti
    Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Via Roma, 55, I 56126 Pisa, Italy
    Eur J Pharmacol 619:8-14. 2009
  5. pmc Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1
    Guido Bocci
    Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Neoplasia 14:833-45. 2012
  6. pmc Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
    Giacomo Allegrini
    Division of Medical Oncology, Pontedera, Pisa, Italy
    Angiogenesis 15:275-86. 2012
  7. doi request reprint Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis
    Luigi Coltelli
    University of Pisa, Via Roma, 55, I 56126 Pisa, Italy
    Pharmacogenomics 10:1225-9. 2009
  8. ncbi request reprint Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients
    Fotios Loupakis
    Division of Medical Oncology, Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Italy
    Curr Cancer Drug Targets 10:37-45. 2010
  9. doi request reprint Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells
    Guido Bocci
    Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma, Pisa, Italy
    Biochem Pharmacol 81:1309-16. 2011
  10. doi request reprint Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1
    Teresa Di Desidero
    MD, PhD, Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
    J Clin Endocrinol Metab 98:E1465-73. 2013

Collaborators

Detail Information

Publications50

  1. ncbi request reprint The effect of osteogenic growth peptide (OGP) on proliferation and adhesion of HEMC-1 human endothelial cells
    Guido Bocci
    Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy
    Pharmacol Res 45:21-5. 2002
    ..These in vitro findings may suggest a possible administration of OGP, as a haematopoietic factor, to patients affected by pathological conditions involving angiogenesis...
  2. pmc Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo
    Bastianina Canu
    Division of Pharmacology, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Neoplasia 13:217-29. 2011
    ..To demonstrate the synergistic antiproliferative and proapoptotic activity of irinotecan and axitinib in vitro and the improvement of the in vivo effects on angiogenesis and pancreatic cancer...
  3. doi request reprint CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo
    Alessandro Antonelli
    Department of Internal Medicine, University of Pisa, School of Medicine, Via Roma, 67, 56100, Pisa, Italy
    J Clin Endocrinol Metab 97:E528-36. 2012
    ..We have studied the antitumor activity of a novel cyclic amide, CLM94, with anti-vascular endothelial growth factor (VEGF) receptor-2 and antiangiogenic activity in primary anaplastic thyroid cancer (ATC) cells in vitro and in vivo...
  4. doi request reprint Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer
    Anna Fioravanti
    Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Via Roma, 55, I 56126 Pisa, Italy
    Eur J Pharmacol 619:8-14. 2009
    ..The metronomic concept might not universally apply to every cytotoxic drug in colorectal cancer and metronomic combination regimens should be used with caution...
  5. pmc Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1
    Guido Bocci
    Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Neoplasia 14:833-45. 2012
    ..To evaluate the antitumor and antiangiogenic activity of metronomic ceramide analogs and their relevant molecular mechanisms...
  6. pmc Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
    Giacomo Allegrini
    Division of Medical Oncology, Pontedera, Pisa, Italy
    Angiogenesis 15:275-86. 2012
    ..To evaluate UFT and cyclophosphamide (CTX) based metronomic chemotherapy plus celecoxib (CXB) for the treatment of patients with heavily pre-treated advanced gastrointestinal malignancies...
  7. doi request reprint Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis
    Luigi Coltelli
    University of Pisa, Via Roma, 55, I 56126 Pisa, Italy
    Pharmacogenomics 10:1225-9. 2009
    ....
  8. ncbi request reprint Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients
    Fotios Loupakis
    Division of Medical Oncology, Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Italy
    Curr Cancer Drug Targets 10:37-45. 2010
    ..This review aims at resuming the state-of-the-art about the role of VEGF pathway inhibitors in the treatment of mCRC and at focusing on the present knowledge about candidate biomarkers as predictors of activity and toxicity...
  9. doi request reprint Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells
    Guido Bocci
    Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma, Pisa, Italy
    Biochem Pharmacol 81:1309-16. 2011
    ....
  10. doi request reprint Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1
    Teresa Di Desidero
    MD, PhD, Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
    J Clin Endocrinol Metab 98:E1465-73. 2013
    ..Sunitinib showed promising preliminary results against anaplastic thyroid cancer (ATC), and it has been used for some patients who are ineligible for clinical trials...
  11. ncbi request reprint Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients
    Federica Amatori
    Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Pharmacogenet Genomics 16:809-16. 2006
    ..To compare thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) gene polymorphism and expression in colorectal cancer (CRC), and normal mucosa in chemotherapy-naïve patients...
  12. ncbi request reprint In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma
    Cecilia Barbara
    Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Via Roma, 55 I 56126 Pisa, Italy
    Eur J Pharmacol 549:27-34. 2006
    ..In conclusion (NH3)2Pt(triacid) is a tolerable and active platinum derivative endowed by a preclinical antitumour activity by oral route...
  13. ncbi request reprint Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation
    Giacomo Allegrini
    U O Oncologia Medica, Presidio Ospedaliero, Viale Alfieri 36, 57124, Livorno, and Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Italy
    Cancer Chemother Pharmacol 58:585-93. 2006
    ..The main purpose of this study was to investigate possible interactions between CPT-11 pharmacokinetics and thalidomide to explain the previously described gastrointestinal toxicity reduction...
  14. ncbi request reprint Angiogenesis and VEGF expression in pre-invasive lesions of the human breast
    Paolo Viacava
    Division of Surgical, Molecular and Ultrastructural Pathology, Department of Oncology, University of Pisa and Pisa University Hospital, Pisa, Italy
    J Pathol 204:140-6. 2004
    ..No correlation was found between VEGF expression and the degree and/or type of vascularization...
  15. ncbi request reprint A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity
    Guido Bocci
    Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Clin Pharmacol Ther 80:384-95. 2006
    ....
  16. doi request reprint VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration
    Stefano Lazzeri
    Ophthalmology Unit, University of Pisa, Pisa, Italy
    Pharmacogenomics 14:623-30. 2013
    ..To investigate the association between VEGF gene SNPs and early response to intravitreal ranibizumab for exudative age-related macular degeneration...
  17. ncbi request reprint Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients
    Antonello Di Paolo
    Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Curr Clin Pharmacol 1:311-23. 2006
    ....
  18. doi request reprint Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer
    Alessandro Antonelli
    Department of Internal Medicine, University of Pisa, School of Medicine, Via Roma 67, I 56100, Pisa, Italy
    J Clin Endocrinol Metab 96:E288-96. 2011
    ..We have studied the antitumoral activity of two new pyrazolo[3,4-d]pyrimidine compounds (CLM3 and CLM29) in primary papillary dedifferentiated thyroid cancer (DePTC) cells...
  19. pmc The pharmacological bases of the antiangiogenic activity of paclitaxel
    Guido Bocci
    Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy
    Angiogenesis 16:481-92. 2013
    ..Thus, the preclinical data of paclitaxel may be exploited to implement a novel and rational therapeutic strategy to control tumor progression in patients...
  20. ncbi request reprint Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity
    Antonello Di Paolo
    Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy
    Curr Drug Metab 12:932-43. 2011
    ..In the present review, pharmacokinetic and pharmacogenetic markers will be discussed...
  21. ncbi request reprint Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens
    Romano Danesi
    Division of Pharmacology and Chemotherapy, Department of Oncology, University of Pisa, Italy
    Clin Colorectal Cancer 4:344. 2005
  22. ncbi request reprint Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules
    Paolo Viacava
    Division of Surgical, Molecular and Ultrastructural Pathology, Department of Oncology, University of Pisa, Pisa, Italy
    Thyroid 17:191-7. 2007
    ....
  23. doi request reprint 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer
    Antonello Di Paolo
    Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Clin Cancer Res 14:2749-55. 2008
    ....
  24. ncbi request reprint Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine
    Guido Bocci
    Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Via Roma, 55, I 56126 Pisa, Italy
    Eur J Pharmacol 498:9-18. 2004
    ....
  25. doi request reprint Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration
    Elisa Agosta
    Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma, 55 56125, Pisa, Italy
    Pharmacogenomics 13:1037-53. 2012
    ....
  26. ncbi request reprint Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling
    Antonello Di Paolo
    Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, 56126 Pisa, Italy
    Ther Drug Monit 27:362-8. 2005
    ....
  27. ncbi request reprint Microvessel density in human normal and neoplastic parathyroids
    Paolo Viacava
    Division of Surgical, Molecular and Ultrastructural Pathology, Department of Oncology, University of Pisa, Via Roma, 55, 56126 Pisa, Italy
    Endocr Pathol 17:175-81. 2006
    ..Therefore, angiogenesis in parathyroid adenomas and carcinomas appears to be an early event, which does not follow a parallel increase in size...
  28. doi request reprint Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients?
    Andrea Fontana
    Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy
    Drugs Aging 27:689-96. 2010
    ..Therefore, evaluation of metronomic chemotherapy strategies in prospective, randomized, phase II/III clinical studies of elderly patients with metastatic prostate cancer appears to be warranted...
  29. doi request reprint Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections
    Antonello Di Paolo
    Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy
    Int J Antimicrob Agents 42:250-5. 2013
    ..The present model may be applied in clinical settings for a TDM routine on the basis of a sparse blood sampling protocol...
  30. doi request reprint EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis
    Francesco Crea
    Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy
    Cancer Metastasis Rev 31:753-61. 2012
    ..Based on this evidence, we propose the development of EZH2 inhibitors as anti-angiogenic and anti-metastatic therapy...
  31. ncbi request reprint 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice
    Federico Innocenti
    Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, I 56126 Pisa, Italy
    Toxicol Appl Pharmacol 203:106-13. 2005
    ..This effect seems to be ascribed to a reduction of viable hepatocytes, rather than to an inactivation of DPD activity...
  32. ncbi request reprint Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy
    Giuseppe Pasqualetti
    University of Pisa, Division of Pharmacology and Chemotherapy, Department of Internal Medicine, Via Roma, 55, I 56126 Pisa, Italy
    Pharmacogenomics 8:49-66. 2007
    ....
  33. doi request reprint A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma
    Marialuisa Polillo
    Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Ther Drug Monit 32:200-5. 2010
    ....
  34. doi request reprint The possible role of chemotherapy in antiangiogenic drug resistance
    Guido Bocci
    Division of Pharmacology, Department of Internal Medicine, University of Pisa, Via Roma 55, Pisa 56126, Italy
    Med Hypotheses 78:646-8. 2012
    ..In conclusion, the consequences of our hypothesis could be promptly translated into the preclinical studies and verified in clinical trials, involving cancer patients resistant to chemotherapy plus antiangiogenic drug schedules...
  35. pmc Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
    Marzia Del Re
    Division of Pharmacology, Department of Internal Medicine, University of Pisa, 55, Via Roma, 56126 Pisa, Italy
    EPMA J 1:495-502. 2010
    ..However, the identification of deficient DPD genotypes may help identify poor-metabolizer patients at risk of developing potentially life-threatening toxicities after standard doses of fluoropyrimidines...
  36. ncbi request reprint Biologic basis of ovarian metastasis of colorectal cancer
    Romano Danesi
    Division of Pharmacology and Chemotherapy, Department of Oncology, University of Pisa, Italy
    Clin Colorectal Cancer 3:223-4. 2004
  37. ncbi request reprint A new biometric tool for three-dimensional subcutaneous tumor scanning in mice
    Guido Bocci
    Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy
    In Vivo 28:75-80. 2014
    ..Aim: To propose an innovative methodology for the monitoring of the evolution of induced subcutaneous tumors in mice...
  38. ncbi request reprint Drug therapeutic failures in emergency department patients. A university hospital experience
    Alessandro Franceschi
    Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy
    Pharmacol Res 49:85-91. 2004
    ..In conclusion, our results suggest that DTFs represent an important cause of emergency department admission, particularly in elderly subjects treated with pharmacological associations...
  39. pmc Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients
    Romano Danesi
    Division of Pharmacology and Chemotherapy, Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Via Roma 55, Italy
    Br J Clin Pharmacol 53:508-18. 2002
    ..To investigate the pharmacokinetics and pharmacodynamics of epirubicin and paclitaxel in combination, as well as the effects of paclitaxel and its vehicle Cremophor EL on epirubicin metabolism...
  40. ncbi request reprint Drug distribution in tumors: mechanisms, role in drug resistance, and methods for modification
    Antonello Di Paolo
    Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Via Roma 55, 56126 Pisa, Italy
    Curr Oncol Rep 9:109-14. 2007
    ..The evaluation of liposomal and nanoparticle formulations and the characterization of newer bioreductive agents and drugs that should normalize tumor vasculature are in progress...
  41. pmc Definition of the microvascular pattern of the normal human adult mammary gland
    Antonio G Naccarato
    Department of Oncology, Division of Surgical, Molecular and Ultrastructural Pathology, University of Pisa, Italy
    J Anat 203:599-603. 2003
    ..4 +/- 1.5) in lobules and ducts, respectively. PR expression levels were in the range 10-13% (11.1 +/- 1.6) and 14-17% (15.2 +/- 1.4), respectively. No correlation was found between ER/PR expression and vascularization parameters...
  42. ncbi request reprint Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor
    Guido Bocci
    Molecular and Cell Biology Research, Sunnybrook and Women s College Health Sciences Centre, Department of Medical Biophysics, University of Toronto, S 217, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Eur J Pharmacol 477:17-21. 2003
    ..These results may have implications in terms of both increasing anti-tumor efficacy, mediated by antiangiogenic mechanisms, and reducing toxic side effects...
  43. ncbi request reprint A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma
    John M L Ebos
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, S 217, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Mol Cancer Res 2:315-26. 2004
    ....
  44. ncbi request reprint Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies
    Guido Bocci
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    Cancer Res 64:6616-25. 2004
    ..Plasma VEGF should be considered as a possible surrogate pharmacodynamic marker for determining the optimal biological dose of antibody drugs that block VEGFR-2 (KDR) activity in a clinical setting...
  45. ncbi request reprint Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity
    Fotios Loupakis
    J Clin Oncol 25:1816-8. 2007
  46. ncbi request reprint Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs
    Guido Bocci
    Molecular and Cell Biology Research, Sunnybrook and Women s College Health Sciences Centre, Department of Medical Biophysics, University of Toronto, Toronto, Ontario, M4N 3M5 Canada
    Cancer Res 62:6938-43. 2002
    ....
  47. ncbi request reprint Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water
    Shan Man
    Departments of Medical Biophysics, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5 Canada
    Cancer Res 62:2731-5. 2002
    ..o. metronomic chemotherapy regimen, which proved safe, reasonably efficacious, and potentially applicable to chronic treatment. Such a regimen may be particularly well suited for integration with antiangiogenic drugs...
  48. pmc Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
    Guido Bocci
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, and Department of Medical Biophysics, University of Toronto, S 217, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Proc Natl Acad Sci U S A 100:12917-22. 2003
    ..Taken together, the results implicate TSP-1 as a secondary mediator of the antiangiogenic effects of at least some low-dose metronomic chemotherapy regimens...
  49. ncbi request reprint Three-dimensional in vitro culture of endometrial explants mimics the early stages of endometriosis
    Alessandro Fasciani
    Department of Obstetrics and Gynecology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Fertil Steril 80:1137-43. 2003
    ..To reproduce the earliest phases of endometriosis using a new in vitro model in which cells from a cultured endometrial fragment can proliferate, invade, reconstitute new endometrial-like tissue, and generate blood vessels...
  50. ncbi request reprint Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose
    Yuval Shaked
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Curr Cancer Drug Targets 5:551-9. 2005
    ..Finally, another promising marker we discuss is soluble VEGFR-2...